CoChat

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

Objective: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options. Design: A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories. Participants: All patients diagnosed with aHUS were included; no age restrictions were used. Interventions: Eculizumab compared with current treatment options. Identification of studies: 12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and contacting clinical experts. Reference lists of relevant articles were checked for additional studies. Results: 2 small, uncontrolled prospective multinational, multicentre studies and one small uncontrolled multinational, multicentre retrospective study were included. No meta-analyses were performed. Compared with baseline measures, thrombotic microangiopathy event-free status was achieved in 84% of patients in the prospective studies. Adverse events, as documented by enrolling investigators were frequent, with upper-respiratory tract infection affecting a third of patients. No deaths or episodes of meningitis or meningococcal septicaemia occurred in the prospective studies. Results of the study extension phases up to 114 weeks indicate that the benefits of the treatment are sustained. Conclusions: Eculizumab is clinically effective for the treatment of aHUS. Further research is needed to evaluate eculizumab, ideally using patient-related clinical outcomes. If randomised studies are not feasible, study investigators should ensure that the threat of bias is minimised in future studies of eculizumab with respect to the reporting of patient recruitment and selection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2013-003573

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 6

  1. Gasser, 1955, Hamolytisch-uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien, Schweiz Med Wochenschr, 85, 905
  2. Legendre C, Babu S, Furman R, et al. Safety & efficacy of eculizamab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial. J Am Soc Nephrol 2011;21:201.
  3. Licht, 2011, A phase II study of eculizumab in adolescent/adult patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion: interim efficacy and safety analysis, Pediatr Nephrol, 26, 1591
  4. Licht, 2011, A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) receiving chronic plasma exchange/infusion: interim analysis, J Thromb Haemost, 9, 499
  5. Simonetti, 2011, Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study, Pediatr Nephrol, 26, 1663
  6. Hillmen, 2003, Eculizumab, a C5 complement-blocking antibody, controls hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) with responses maintained over a prolonged period of therapy, Blood, 102, 509a

Cited by

See all 116

Metadata

Authors
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A.
Affiliations
  • University of Sheffield (GB)
  • Imperial College London (GB)
Corresponding author
Kaltenthaler, Eva
Venue
BMJ Open
Publisher
BMJ
Published
2013-11
Volume
3
Issue
11
Pages
e003573
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2143604857
Cited by
110
References
56
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 11 · 2021: 4 · 2020: 9 · 2019: 13 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 9 · 2014: 10
FWCI
0.93
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc)
Funders
  • Alexion Pharmaceuticals
  • Wellcome Trust (WT085226)
  • National Institute for Health and Care Research
  • Health Technology Assessment Programme
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords
eculizumab, atypical hemolytic uremic syndrome, thrombotic microangiopathy, complement inhibition, treatment efficacy, adverse events, upper respiratory tract infection, long-term treatment outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). https://app.cochat.ai/papers/10.1136/bmjopen-2013-003573
The paper
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013). A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. https://doi.org/10.1136/bmjopen-2013-003573

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.